Investigational drug · Phase 2
M1774
Also called: Tuvusertib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
14
Any phase or sponsor naming "M1774"
First trial start
2023
Sep 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "M1774", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Ovarian Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "M1774" as an intervention, largest first.
EMD Serono Research & Development Institute, Inc.Industry
NCT04170153 · 161 participants · Start Dec 20, 2019 · Primary completion Oct 14, 2026
Drug: M1774; Niraparib · For: Metastatic or Locally Advanced Unresectable Solid Tumors
Sites: Boston, Massachusetts; Austin, Texas; Dallas, Texas · 16 sites in all
EMD Serono Research & Development Institute, Inc.Industry
NCT05396833 · 120 participants · Start Jun 7, 2022 · Primary completion Jul 14, 2026
Drug: Tuvusertib; Lartesertib and 1 more · For: Metastatic or Locally Advanced Unresectable Solid Tumors
Sites: Santa Rosa, California; Miami, Florida; Augusta, Georgia · 22 sites in all
National Cancer Institute (NCI)NIH
NCT05687136 · 66 participants (planned) · Start Jun 7, 2024 · Primary completion Aug 31, 2027
Drug: Peposertib; Tuvusertib · For: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
Sites: Bethesda, Maryland; Boston, Massachusetts; Mineola, New York · 7 sites in all
National Cancer Institute (NCI)NIH
NCT05950464 · 65 participants (planned) · Start Dec 18, 2023 · Primary completion Jun 30, 2027
Drug: BET Bromodomain Inhibitor ZEN-3694; Tuvusertib · For: Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma and 6 more
Sites: Augusta, Georgia; Chicago, Illinois; Iowa City, Iowa · 14 sites in all
EMD Serono Research & Development Institute, Inc.Industry
NCT06433219 · 63 participants · Start Oct 30, 2024 · Primary completion Aug 11, 2026
Drug: Tuvusertib (M1774); Niraparib and 1 more · For: Ovarian Cancer
Sites: Little Rock, Arkansas; San Francisco, California; Columbus, Georgia · 84 sites in all
EMD Serono Research & Development Institute, Inc.Industry
NCT05882734 · 61 participants · Start Sep 13, 2023 · Primary completion Jul 15, 2026
Drug: M1774; Cemiplimab · For: Non-Small Cell Lung Cancer
Sites: Santa Monica, California; Pittsburgh, Pennsylvania; Knoxville, Tennessee · 54 sites in all
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT06421935 · 60 participants · Start Aug 7, 2024 · Primary completion Feb 22, 2027
Drug: M9466; Tuvusertib and 2 more · For: Advanced Solid Tumor
Sites: New York, New York; Houston, Texas; Adelaide, Australia · 20 sites in all
- I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast CancersNot yet recruiting
Institut Paoli-CalmettesAcademic, hospital or other
NCT05986071 · 57 participants (planned) · Start May 1, 2024 · Primary completion Apr 1, 2027
Drug: M1774; Fulvestrant injection · For: Breast Cancer
Sites: Marseille, France
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05947500 · 50 participants (planned) · Start May 21, 2024 · Primary completion Jan 1, 2028
Drug: Avelumab; Tuvusertib · For: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma and 3 more
Sites: Irvine, California; La Jolla, California; Los Angeles, California · 51 sites in all
- Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05691491 · 42 participants (planned) · Start Sep 28, 2023 · Primary completion Mar 1, 2027
Drug: Temozolomide; Tuvusertib · For: Advanced Malignant Solid Neoplasm; Advanced Microsatellite Stable Colorectal Carcinoma; Hematopoietic and Lymphatic System Neoplasm and 4 more
Sites: Irvine, California; La Jolla, California; Orange, California · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.
Zuidema A, Nijland L, van Megesen K, et al. · Br J Cancer 2026
- Duocarmycin-Bearing Antibody-Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL-4 Xenograft Model.
Tanaka T, Sugiyama A, Sakata J, et al. · Cancer Med 2026
- Structure Elucidation and Initial Characterization of a N-glucuronide Metabolite (M1) of Tuvusertib.
Lang B, Schieferstein H, Thede K, et al. · Eur J Drug Metab Pharmacokinet 2026
- Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Mukker JK, Diderichsen PM, Hellmann F, et al. · Clin Pharmacol Ther 2026
- Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells.
Roehrle J, Perugachi-Heinsohn A, Gatzemeier F, et al. · Sci Rep 2026
- An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.
Mukker JK, Yap TA, Tolcher AW, et al. · Clin Transl Sci 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.